30 & 31 January 2017
PARIS - Palais des Congrès

International Conference on the Management of Liver Diseases
Organised by Pr Patrick Marcellin, APHC

Organising Committee
Michelle Martinot-Peignoux, Monelle Muntlak
Hôpital Beaujon, APHP - INSERM CRI - Université Paris-Diderot

Scientific Committee
Marc Bourlière, Massimo Colombo, Rafael Esteban,
Graham Foster, Michael Fried, Michael Manns

www.aphc.info

Follow us on Twitter: @PHC_off #PHC2017
Dear Colleagues and Friends,

We are pleased to welcome you at the 10th Paris Hepatology Conference (PHC).

As usual, the meeting will provide state of the art information on the management of patients with liver disease by highly renowned international experts who will present the most recent results in the field and their clinical applications.

Thanks to the outstanding progress made in the treatment of hepatitis C with the new direct acting antiviral combinations, almost all these patients can now potentially be cured, including formerly «difficult to treat» patients (those with cirrhosis, co-infection with HIV and transplantation…). These combinations are well tolerated and highly effective with shorter treatment (high SVR rates after 12 weeks of treatment and a significant proportion of the population that responds after only 8 weeks).

Indeed, these advances raise the issue of how to facilitate access to treatment in more patients to reach the new realistic objective of eradicating hepatitis C. Eradication of HCV is now a dream shared by experts all over the world. To reach this goal a joint strategy is necessary involving different regions and countries. This will be debated during this PHC.

The goal of therapy in hepatitis B is now more ambitious: HBsAg loss and a clinical cure. Extensive research is focusing on viral eradication by developing new drugs with different mechanisms of action and different targets. Hopefully, within the next five years, safe combinations of potent antivirals, an effective immune-modulator and a drug interfering with protein synthesis or assembly will become available, with the ultimate goal of silencing or eradicating cccDNA.

For the first time this year, the PHC program includes outstanding experts in specific sessions and workshops to address unmet needs: NASH, HCC and end-stage liver disease, all difficult diseases with clinical issues commonly faced by all specialists.

As in previous PHCs, interactive discussions and specific lunch workshops have been organized to apply results to the management of real life patients. Indeed, the ultimate goal of the PHC 2017 is to review the most current knowledge and discuss their therapeutic applications with the most experienced experts to provide optimal therapies and the best chance of cure to as many patients as possible, worldwide.

We wish you a fruitful and pleasant meeting,

Amitiés,

Professor Patrick Marcellin
President of the 10th Paris Hepatology Conference
08.30 - 08.40  INTRODUCTION
Patrick Marcellin (France)

08.40 - 10.00  HEPATITIS C - SESSION 1
Chairs: Marc Bourlière (France), Rafael Esteban (Spain)

08.40  Universal Hepatitis C treatment: strategies for simplification
Tarik Asselah (France)

08.55  Policies for HCV elimination
Angelos Hatzakis (Greece)

09.10  Impact of therapy on the QOL
Geoffrey Dusheiko (UK)

09.45  Round table discussion

10.00 - 10.30  Coffee break

10.30 - 11.30  HEPATITIS C - SESSION 2
Chairs: Nezam Afdhal (USA), Antonio Craxi (Italy)

10.30  Impact of therapy on metabolism and public health
Mitchell Shiffman (USA)

10.45  Special populations
Stefan Zeuzem (Germany)

11.00  Results in real life
Robert Flisiak (Poland)

11.15  Round table discussion

11.30 - 11.50  CLINICAL CASE
Impact of therapy in a patient F1
Eugene Schiff (USA)

11.50 - 12.30  STATE OF THE ART LECTURE & AWARD
Chair: Patrick Marcellin (France)

From HCV to HBV cure
Raymond Schinazi (USA)

12.30 - 14.30  LUNCH WORKSHOPS

14.30 -15.30  NASH SESSION
Chairs: Arun Sanyal (USA), Lawrence Serfaty (France)

14:30  Epidemiology of NASH
Stefano Bellentani (Switzerland)

14:45  Pathology of NASH
Pierre Bedossa (France)

15:00  Lifestyle intervention in NASH
Vlad Ratziu (France)

15:15  Therapies in NASH
Arun Sanyal (USA)

15:30 - 15:50  Coffee break

15.50 - 17.40  AROUND THE WORLD TABLE: ACCESS TO THERAPY
Introduction - Massimo Colombo (Italy)

WESTERN COUNTRIES
Chair: Massimo Colombo (Italy)
Speakers: Maria Buti (Spain), Antonio Craxi (Italy), Graham Foster (UK),
Michael Fried (USA), Victor de Ledinghen (France), Stefan Zeuzem (Germany)

OTHER COUNTRIES
Chair: Michael Fried (USA)
Speakers: Mustapha Benazzouz (Morocco), Robert Flisiak (Poland),
Jinlin Hou (China), Vasily Isakov (Russia), Adriana Popescu (Romania),
Raymundo Parana Filho (Brazil)

17.40 - 18.00  STATE OF THE ART LECTURE
Chair: Tarik Asselah (France)

The future of research on viral hepatitis
Charles Rice (USA)

18.00 - 18.10  TAKE HOME MESSAGES
Marc Bourlière (France)

18.10 - 18.20  CONCLUSION
Patrick Marcellin (France)

19.30  Congress dinner
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 - 08.40</td>
<td>INTRODUCTION</td>
<td>Patrick Marcellin (France)</td>
<td></td>
</tr>
<tr>
<td>08.40 - 10.00</td>
<td>HEPATITIS B - SESSION 1</td>
<td>Chairs: Ji Dong Jia (China), Georgios Papatheodoridis (Greece)</td>
<td>Georges Lau (Hong Kong)</td>
</tr>
<tr>
<td>08.40</td>
<td>How to manage HBV patients in 2017?</td>
<td></td>
<td>Seng-Gee Lim (Singapore)</td>
</tr>
<tr>
<td>08.55</td>
<td>When can we stop NUCS in patients with chronic hepatitis B?</td>
<td></td>
<td>Pietro Lampertico (Italy)</td>
</tr>
<tr>
<td>09.10</td>
<td>Long term impact of antiviral therapy (NUCs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.25</td>
<td>Round table discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00 - 10.30</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30 - 11.30</td>
<td>HEPATITIS B - SESSION 2</td>
<td>Chairs: Michael Manns (Germany), Shiv Sarin (India)</td>
<td>Fabien Zoulim (France)</td>
</tr>
<tr>
<td>10.30</td>
<td>New targets for HBV therapies</td>
<td></td>
<td>Edward Gane (New Zealand)</td>
</tr>
<tr>
<td>10.45</td>
<td>New anti-HBV strategies</td>
<td></td>
<td>Michael Manns (Germany)</td>
</tr>
<tr>
<td>11.00</td>
<td>How to improve access to therapy for HBV patients?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.15</td>
<td>Round table discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30 - 12.45</td>
<td>END-STAGE LIVER DISEASE</td>
<td>Chairs: Richard Moreau (France), Didier Samuel (France)</td>
<td>Jaime Bosh (Spain)</td>
</tr>
<tr>
<td>11.30</td>
<td>Prevention and treatment of variceal hemorrhage in 2017</td>
<td></td>
<td>Paolo Angeli (Italy)</td>
</tr>
<tr>
<td>11.45</td>
<td>Why and how to assess renal function in cirrhosis</td>
<td></td>
<td>Ulrich Beuers (Netherland)</td>
</tr>
<tr>
<td>12.00</td>
<td>Management of cholestatic diseases in 2017</td>
<td></td>
<td>François Durand (France)</td>
</tr>
<tr>
<td>12.15</td>
<td>The future of liver transplantation for viral hepatitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30</td>
<td>Round table discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.45 - 14.30</td>
<td>LUNCH WORKSHOPS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30 - 14.50</td>
<td>TWO PROGRAMS OF HCV ERADICATION</td>
<td>Chair: Graham Foster (UK)</td>
<td>Gamal Esmat (Egypt), Tengiz Tsertsvadze (Georgia)</td>
</tr>
<tr>
<td>14.50</td>
<td>The molecular road map of HCC</td>
<td>Jessica Zucman Rossi (France)</td>
<td></td>
</tr>
<tr>
<td>15.05</td>
<td>The impact of anti HCV DAAs on HCC</td>
<td>Jordi Bruix (Spain)</td>
<td></td>
</tr>
<tr>
<td>15.20</td>
<td>Reconsidering OLT to treat HCC in an era of donors shortage</td>
<td>Didier Samuel (France)</td>
<td></td>
</tr>
<tr>
<td>15.35</td>
<td>Round table discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.50 - 16.00</td>
<td>TAKE HOME MESSAGES</td>
<td>Michael Fried (USA)</td>
<td></td>
</tr>
<tr>
<td>16.00 - 16.10</td>
<td>CONCLUSION</td>
<td>Patrick Marcellin (France)</td>
<td></td>
</tr>
</tbody>
</table>
**Room 242A**

Treatment of transplanted HCV patients: when and how?

**Chair:** Jordi Bruix (Spain)

**Speakers:** Maria Buti Ferret (Spain), Claire Francoz (France)

---

**Room 252B**

Need to assess HCV resistance to DAAs: is it useful and when?

**Chair:** Edward Gane (New Zealand)

**Speakers:** Philippe Halfon (France), Stéphane Chevaliez (France)

---

**Room 242B**

Long term benefits and side effects of NUC therapy: where are we?

**Chair:** Georgios Papatheodoridis (Greece)

**Speakers:** Petr Urbánek (Czech Republic), Vincent Leroy (France)

---

**Room 241**

How to diagnose NASH?

**Chair:** Vlad Ratziu (France)

**Speakers:** Pierre Bedossa (France), Ana Carolina Cardoso (Brazil)

---

**Room 242B**

The microbiome in liver diseases: Where are we?

**Chair:** Arun Sanyal (USA)

**Speaker:** Gabriel Perlemuter (France)

---

**Room 243**

Treatment of HCC in real life

**Chair:** Massimo Colombo (Italy)

**Speakers:** George Lau (Hong Kong), Vincent Di Martino (France)

---

**Room 252A**

Optimal management of ascites

**Chair:** Peter Ferenci (Austria)

**Speakers:** Dominique Thabut (France), Paolo Angeli (Italy)

---

**Room 251**

Management of autoimmune hepatitis

**Chair:** Michael Manns (Germany)

**Speakers:** Vasily Isakov (Russia), Pierre-Emmanuel Rautou (France)

---

**Room 241**

How to manage patients with NASH?

**Chair:** Lawrence Serfaty (France)

**Speakers:** Raluca Pais (France), Laurent Castera (France)

---

**Room 243**

Diagnostic et prise en charge d’un patient avec NASH

(French speaking lunch workshop)

**Chairs:** Daniel Dhumeaux (France), Jean-François Cadranel (France)

**Speakers:** Denis Ouzan (France), Adriana Popescu (Romania)
GENERAL INFORMATION

CONFERENCE DATES AND VENUE
From Monday 30th to Tuesday 31st January 2017
At the “Palais des Congrès”
2, place de la Porte Maillot
75017 Paris – France

CONFERENCE REGISTRATION DESK
30th & 31st January, from 7:30 am.
Welcome desks are organised on level 2 of the Palais des Congrès in Foyer Bleu next to the Amphithéâtre Bleu. You will be able to retrieve your access badge, congress bag and proceedings.

CONGRESS OFFICE
Quadrature Santé / PHC 2017
43 rue des Tilleuls
92100 Boulogne-Billancourt
Phone: +33 (0)1 40 68 12 34
Fax: +33 (0)1 40 68 34 34
Contact: contact@aphc.info
www.aphc.info

CONGRESS HOTELS
Hyatt Regency Paris Étoile
3 place du Général Koenig
75017 Paris
Tel: +33 (0) 1 40 68 12 34
Méridien Etoile Hotel
81 boulevard Gouvion St-Cyr
75 017 Paris
Tel: +33 (0) 1 40 68 34 34

CONGRESS DINNER
Monday 30th January at the Pavillon Dauphine
Place du Maréchal de Lattre de Tassigny,
75116 Paris
Buses will leave from the Palais des Congrès from 7:00 p.m.
Dress code: cocktail attire

CME CONTINUOUS MEDICAL EDUCATION ACCREDITATION
The “APHC” is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.
The 10th Paris Hepatology Conference is designated for a maximum of (or “for up to”) 10 European CME credits (ECMEC).

LIVER INTERNATIONAL
The PHC Liver International Supplement is available online at the following address:

LUNCHES
2 types of lunches are organised each day:
- Lunch Workshops (Level 2).
The number of seats is limited.
- Regular lunches are organised in Salon Arc en Ciel (Level 4).

OFFICIAL LANGUAGE
The official language of the conference is English.

CONGRESS DINNER
Monday 30th January at the Pavillon Dauphine
Place du Maréchal de Lattre de Tassigny,
75116 Paris
Buses will leave from the Palais des Congrès from 7:00 p.m.
Dress code: cocktail attire

CME CONTINUOUS MEDICAL EDUCATION ACCREDITATION
The “APHC” is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.
The 10th Paris Hepatology Conference is designated for a maximum of (or “for up to”) 10 European CME credits (ECMEC).

LIVER INTERNATIONAL
The PHC Liver International Supplement is available online at the following address:

LUNCHES
2 types of lunches are organised each day:
- Lunch Workshops (Level 2).
The number of seats is limited.
- Regular lunches are organised in Salon Arc en Ciel (Level 4).

OFFICIAL LANGUAGE
The official language of the conference is English.

CONGRESS DINNER
Monday 30th January at the Pavillon Dauphine
Place du Maréchal de Lattre de Tassigny,
75116 Paris
Buses will leave from the Palais des Congrès from 7:00 p.m.
Dress code: cocktail attire

CME CONTINUOUS MEDICAL EDUCATION ACCREDITATION
The “APHC” is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.
The 10th Paris Hepatology Conference is designated for a maximum of (or “for up to”) 10 European CME credits (ECMEC).

LIVER INTERNATIONAL
The PHC Liver International Supplement is available online at the following address:

LUNCHES
2 types of lunches are organised each day:
- Lunch Workshops (Level 2).
The number of seats is limited.
- Regular lunches are organised in Salon Arc en Ciel (Level 4).

OFFICIAL LANGUAGE
The official language of the conference is English.